Real-time immune monitoring through liquid biopsies that measure serum cytokine panels (IL-6, TNF-α, IFN-γ) at 2, 6, and 24 hours post-treatment facilitates ultra-early detection of CRS (within a 24- to 72-hour window), triggering preventive interventions (such as tocilizumab and corticosteroids) before the syndrome escalates. This evidence concerns the gene IFNG and congenital rubella syndrome.